A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Conditions

• Psoriatic Arthritis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bimekizumab — DRUG
  Study participants will receive bimekizumab at pre-specified time points.
• Risankizumab — DRUG
  Study participants will receive risankizumab at pre-specified time points.
• Placebo — DRUG
  Study participants will receive placebo at pre-specified time points.

Study Details

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

Key Dates

Start date

Oct 21, 2024

Status verified

Jun 2026

Primary completion

Feb 6, 2026

Completion

Jun 5, 2026

Study Design

Enrollment

684 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Bimekizumab
  Study participants will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding during treatment period.
• Active Comparator: Risankizumab
  Study participants will receive assigned risankizumab dosage regimen and placebo to maintain the blinding during treatment period.

Primary Outcome Measure

American College of Rheumatology 50 (ACR50) at Week 16 [ Time Frame: Week 16 ]

Locations (34)

Related coverage on Hipa.ai

• Bimekizumab Phase 3 Trial for Psoriatic Arthritis Reaches Primary Completion
  Bimekizumab · Feb 6, 2026 · ClinicalTrials.gov

Find similar trials in Gilbert, AZ

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
  Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Stronger Together Psoriatic Arthritis Wellness Study
  Recruiting · Global Healthy Living Foundation · Upper Nyack, New York